Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Countering Public Health Threats

Countering Public Health Threats News & Analysis News From the Food and Drug Administration Immunotherapy for Rare Skin Cancer related risks are pneumonitis, hepatitis, received a placebo. The drug also helped re- Avelumab is the first drug approved for colitis, endocrinopathies, and nephritis. duce off time, and it enhanced quality of life. adults and pediatric patients aged 12 years Another 24-week phase 3 trial with 549 or older who have metastatic Merkel cell patientstakinglevodopawhohadmorethan New Addition to Parkinson Therapy carcinoma(MCC),arare,aggressiveskincan- Safinamide has received FDA approval as an 1.5 hours daily of off time showed that sa- cer. The drug is a checkpoint inhibitor, a form add-on treatment for patients with Parkin- finamide increased daily on time without of immunotherapy approved for several son disease who take levodopa and car- problematic dyskinesia by 1.42 hours com- other types of cancer. bidopa but have “off” episodes, when medi- pared with 0.57-hour for placebo. In addi- About 1500 new MCC diagnoses occur cationdoesn’tadequatelycontrolsymptoms tion, off time decreased while motor func- in the United States annually, and the such as tremor. tion and quality of life improved. incidence rose during the late 1980s and The most common adverse events were ‘90s. Research showed that US rates uncontrolled http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Countering Public Health Threats

Voelker, Rebecca
JAMA , Volume 317 (17) – May 2, 2017
Download PDF
1 page

Countering Public Health Threats

Abstract

News & Analysis News From the Food and Drug Administration Immunotherapy for Rare Skin Cancer related risks are pneumonitis, hepatitis, received a placebo. The drug also helped re- Avelumab is the first drug approved for colitis, endocrinopathies, and nephritis. duce off time, and it enhanced quality of life. adults and pediatric patients aged 12 years Another 24-week phase 3 trial with 549 or older who have metastatic Merkel cell patientstakinglevodopawhohadmorethan New Addition to...
Loading next page...
 
/lp/american-medical-association/countering-public-health-threats-hl08IMHYPQ

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2017.4846
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the Food and Drug Administration Immunotherapy for Rare Skin Cancer related risks are pneumonitis, hepatitis, received a placebo. The drug also helped re- Avelumab is the first drug approved for colitis, endocrinopathies, and nephritis. duce off time, and it enhanced quality of life. adults and pediatric patients aged 12 years Another 24-week phase 3 trial with 549 or older who have metastatic Merkel cell patientstakinglevodopawhohadmorethan New Addition to Parkinson Therapy carcinoma(MCC),arare,aggressiveskincan- Safinamide has received FDA approval as an 1.5 hours daily of off time showed that sa- cer. The drug is a checkpoint inhibitor, a form add-on treatment for patients with Parkin- finamide increased daily on time without of immunotherapy approved for several son disease who take levodopa and car- problematic dyskinesia by 1.42 hours com- other types of cancer. bidopa but have “off” episodes, when medi- pared with 0.57-hour for placebo. In addi- About 1500 new MCC diagnoses occur cationdoesn’tadequatelycontrolsymptoms tion, off time decreased while motor func- in the United States annually, and the such as tremor. tion and quality of life improved. incidence rose during the late 1980s and The most common adverse events were ‘90s. Research showed that US rates uncontrolled

Journal

JAMA – American Medical Association

Published: May 2, 2017

There are no references for this article.